<DOC>
	<DOCNO>NCT02753413</DOCNO>
	<brief_summary>The purpose study assess safety reactogenicity single intramuscular dose GSK Biologicals ' investigational RSV vaccine , healthy , non-pregnant woman age 18 45 year .</brief_summary>
	<brief_title>Safety Reactogenicity Study GlaxoSmithKline ( GSK ) Biologicals ' Investigational Respiratory Syncytial Virus ( RSV ) Vaccine ( GSK3003891A ) Healthy Women</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . Written inform consent obtain subject prior perform study specific procedure . Nonpregnant female , include , 18 45 year age time vaccination . Healthy subject establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination agree continue adequate contraception entire study period . Use investigational nonregistered product study vaccine within 30 day prior study vaccination , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Chronic administration immunosuppressant immunemodifying drug , well administration longacting immunemodifying drug period start 6 month prior study vaccination , plan administration study period . Inhaled topical steroid allow . Administration immunoglobulins and/or blood product period start 3 month study vaccination plan administration study period . Planned administration/administration vaccine foreseen study protocol period start 30 day end 30 day study vaccination , exception license influenza vaccine may administer â‰¥ 15 day study vaccination . Previous experimental vaccination RSV . Family history congenital hereditary immunodeficiency . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History current autoimmune disease . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality determine physical examination and/or Medical History . Lymphoproliferative disorder malignancy within previous 5 year . History hypersensitivity previous dose tetanus , diphtheria , pertussis vaccine component Boostrix . History encephalopathy unknown aetiology occur within 7 day follow previous vaccination pertussiscontaining vaccine . History neurological disorder seizure . History transient thrombocytopenia neurological complication follow previous vaccination diphtheria and/or tetanus . History reaction hypersensitivity likely exacerbate component study vaccine . Hypersensitivity latex . Any medical condition judgment investigator would make intramuscular injection unsafe . Current chronic alcohol consumption and/or drug abuse . Acute disease and/or fever time enrolment . Body mass index ( BMI ) &gt; 40 kg/m2 . Pregnant lactate female . Planned move location prohibit participate trial study end . Any condition investigator judge may interfere study procedure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>Respiratory syncytial virus ( RSV )</keyword>
</DOC>